Oral L-tyrosin for reversing gray hair; a clinical trial
Phase 2
- Conditions
- Gray hairAlternative and Complementary Medicine - Other alternative and complementary medicineSkin - Normal skin development and function
- Registration Number
- ACTRN12613001277730
- Lead Sponsor
- Daniel F Fouladi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Male
- Target Recruitment
- 15
Inclusion Criteria
Normal men with gray hair.
Exclusion Criteria
Secondary gray hair, malnutrition, taking other medications/supplements.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method umber of gray hairs on the frontal, parietal, temporal and occipital regions on both sides, separately.<br>For this purpose, the participants will wear a specially designed yarn hat with holes (10 cm in diameter) on each region of the skull on both sides. An examiner will count gray hairs in each hole separately under direct light and magnification. [baseline, month 3, month 6, month 9.]
- Secondary Outcome Measures
Name Time Method Possible complications of L-tyrosine plus 5-HTP such as problems in appetite, sleep, sexual behavior, temperature and pain sensation, nausea, fatigue, headaches, heartburn, joint pain, mood changes, irritability and changes in heart rate by asking from patients.[During the study period.]
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie L-tyrosine's potential to reverse graying in human hair follicles?
How does oral L-tyrosine supplementation compare to standard-of-care treatments for reversing premature graying?
Are there specific biomarkers that predict response to L-tyrosine in patients with androgenetic alopecia-related graying?
What are the potential adverse events associated with long-term L-tyrosine administration for hair pigmentation?
What combination therapies with L-tyrosine show enhanced efficacy in ACTRN12613001277730 and similar trials?